Cancer immunotherapy (CIT) with antibodies targeting the programmed cell death 1 protein
(PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis have changed the standard of care in …

Hepatocellular carcinoma (HCC), one of the most fatal malignancies in the world, is usually
diagnosed in advanced stages due to late symptom manifestation with very limited …

PURPOSE To develop an evidence-based clinical practice guideline to assist in clinical
decision making for patients with advanced hepatocellular carcinoma (HCC). METHODS …

Patients with advanced hepatocellular carcinoma (HCC) have historically had few options
and faced extremely poor prognoses if their disease progressed after standard-of-care …

Simple Summary Liver cancer is a life-threatening disease. Apart from surgery and catheter-
guided therapies, drugs are a central pillar for its treatment. Clinical trials are research …

Conclusion Herein, we comprehensively review and refine the clinical hallmarks uniquely
associated with ICI therapies, which not only will rejuvenate our assessment of ICI …

For a decade, sorafenib remained the only approved first-line treatment and standard of care
for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly …

Purpose: Chromosomal instability is a hallmark of cancer that results in broad and focal copy-
number alterations (CNAs), two events associated with distinct molecular, immunologic, and …

Advanced hepatocellular carcinoma (HCC) is the most frequent liver cancer. Immunotherapy
has been explored in this disease in order to improve survival outcomes. Nowadays …

The implementation of immune checkpoint inhibitors (ICI) into the clinical management of
different malignancies has largely changed our understanding of cancer treatment. After …